[HTML][HTML] Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small …
CH Gow, YL Chang, YC Hsu, MF Tsai, CT Wu, CJ Yu… - Annals of …, 2009 - Elsevier
Background Mutations of the epidermal growth factor receptor (EGFR) gene in non-small-
cell lung cancer (NSCLC) patients predict the patients who will respond to EGFR tyrosine …
cell lung cancer (NSCLC) patients predict the patients who will respond to EGFR tyrosine …
EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
ZY Chen, WZ Zhong, XC Zhang, J Su, XN Yang… - The …, 2012 - academic.oup.com
Background. Non-small cell lung cancer patients with epidermal growth factor receptor
(EGFR) mutations have mixed responses to tyrosine kinase inhibitors (TKIs). Intertumor …
(EGFR) mutations have mixed responses to tyrosine kinase inhibitors (TKIs). Intertumor …
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non–small cell …
TY Chou, CH Chiu, LH Li, CY Hsiao, CY Tzen… - Clinical cancer …, 2005 - AACR
Purpose: Mutations in epidermal growth factor receptor (EGFR) can be used to predict the
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non–small cell lung cancer treated with epidermal growth …
PA Jänne, BE Johnson - Clinical cancer research, 2006 - AACR
Somatic mutations in the epidermal growth factor receptor (EGFR) have been identified in
patients with advanced non–small cell lung cancer who achieve dramatic clinical and …
patients with advanced non–small cell lung cancer who achieve dramatic clinical and …
Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
Q Zhou, XC Zhang, ZH Chen, XL Yin… - Journal of clinical …, 2011 - ascopubs.org
Purpose Our aim was to determine whether abundance of epidermal growth factor receptor
(EGFR) mutations in tumors predicts benefit from treatment with EGFR–tyrosine kinase …
(EGFR) mutations in tumors predicts benefit from treatment with EGFR–tyrosine kinase …
[HTML][HTML] An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients
I Kawada, K Soejima, H Watanabe, I Nakachi… - Journal of Thoracic …, 2008 - Elsevier
Introduction Epidermal growth factor receptor (EGFR) mutations are strong determinants of
tumor response to EGFR tyrosine kinase inhibitors in non-small cell lung cancers (NSCLCs) …
tumor response to EGFR tyrosine kinase inhibitors in non-small cell lung cancers (NSCLCs) …
[HTML][HTML] De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer
M Takeda, I Okamoto, Y Fujita, T Arao, H Ito… - Journal of Thoracic …, 2010 - Elsevier
Background Somatic mutations in the epidermal growth factor receptor (EGFR) gene are a
predictor of response to treatment with EGFR tyrosine kinase inhibitors (TKIs) in patients with …
predictor of response to treatment with EGFR tyrosine kinase inhibitors (TKIs) in patients with …
[HTML][HTML] Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non …
S Park, AJ Holmes-Tisch, YM Shim, J Kim… - Journal of Thoracic …, 2009 - Elsevier
Introduction: For the identification of the patients who most likely benefit from epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer …
growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer …
High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas
PL Sun, Y Jin, H Kim, CT Lee, S Jheon… - Cancer …, 2013 - Wiley Online Library
BACKGROUND Activating mutations in the epidermal growth factor receptor (EGFR) in non–
small cell lung carcinoma (NSCLC) are associated significantly with responsiveness to …
small cell lung carcinoma (NSCLC) are associated significantly with responsiveness to …
Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer
J Yu, S Kane, J Wu, E Benedettini, D Li, C Reeves… - Clinical Cancer …, 2009 - AACR
Purpose: Activating mutations within the tyrosine kinase domain of epidermal growth factor
receptor (EGFR) are found in approximately 10% to 20% of non–small-cell lung cancer …
receptor (EGFR) are found in approximately 10% to 20% of non–small-cell lung cancer …
相关搜索
- cell lung cancer
- lung cancer metastatic tumors
- lung cancer tyrosine kinase
- receptor tyrosine growth factor
- growth factor kinase inhibitors
- receptor mutations kinase inhibitors
- lung cancer gefitinib treatment
- lung adenocarcinomas mixed response
- lung adenocarcinomas mutation heterogeneity
- lung adenocarcinomas high concordance
- lung cancer antibodies for the detection
- lung cancer relative abundance
- egfr mutation status
- primary tumors molecular biomarkers
- metastatic tumors tyrosine kinase
- receptor tyrosine kinase inhibitors